APLT appliedtherapeutics.com: Accounting Value per Share

Graphic logo of Applied Therapeutics (APLT)

Applied Therapeutics minimizes risks by developing high-cost therapies to combat rare genetic pathologies. An analysis of the book value per share confirms the actual volume of net assets, with the indicator currently at 0.00. High barriers to entry are ensured by strict FDA control and unique patents. The company's innovation potential is currently at its peak as it prepares the final results of late-stage govorestat trials.

Applied Therapeutics, Inc. - APLT Net Assets per Share (period 07/04/2022 - 02/16/2026)

Summary analytical data breakdowns for appliedtherapeutics.com (APLT)

- price and consensus price forecast:
Price Chart Applied Therapeutics|APLT - Price Target Chart
- market capitalization data:
Market Valuation Applied Therapeutics, Inc.|APLT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share Applied Therapeutics|APLT - Book Valuation of Business|Market Value to Book Value Ratio appliedtherapeutics.com|APLT - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Applied Therapeutics|APLT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Applied Therapeutics, Inc.|APLT - Company Total Debt|Debts to Book Capitalization Applied Therapeutics, Inc.
Analysis of all company metrics:Applied Therapeutics APLT
Finished products of appliedtherapeutics.com

Book value per share determines a company's net equity minus all liabilities, reflecting the actual tangible value of an investor's stake. For Applied Therapeutics (APLT), with its focus on high-tech laboratories and a staff of elite biologists, the book value per share of 0.00 serves as an indicator of the resource base for scientific breakthroughs, confirming financial stability during the development of rare disease therapies.

Competitors of Applied Therapeutics (APLT)

VRTX - Net Assets per Single Share|Alnylam Corp (ALNY) - Net Assets per Single Share|INSM - Accounting Value per Share|UTHR (unither.com) - Book Price of a Share|BMRN: Net Assets per Single Share|Net Assets per Share BBIO|BGM - Net Assets per Single Share|Share Book Value Cogent Corp (COGT)|XERS: Book Value per Share|Net Asset Value per Share kerostx.com KROS|ARCT: Book Value per Share|ETON - Accounting Value per Share|Kamada Corp - Book Value per Share|Fulcrum Corp (FULC) - Net Assets per Share|ABEO (Abeona Therapeutics, Inc.) - Book Value per Share|Book Value per Share MREO|Net Assets per Single Share Protalix BioTherapeutics, Inc. (PLX)|Net Assets per Single Share pliantrx.com (PLRX)|Book Value per Share RNTX|GELS - Net Assets per Share|Accounting Value per Share Aytu Therapeutics|CMMB - Share Book Value|Book Value per Share SRXH|Polyrizon (PLRZ) - Net Asset Value per Share|Book Value per Share Aeterna Zentaris Inc (AEZS)|Equity per Share Cyclo Therapeutics, Inc (CYTH)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share